Cargando…

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.

In premenopausal women with advanced breast cancer the luteinising hormone-releasing hormone agonist goserelin (Zoladex, ICI plc) will produce serum levels of oestradiol equivalent to those following surgical oophorectomy or the menopause. This paper reports our further experience of using this drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dixon, A. R., Robertson, J. F., Jackson, L., Nicholson, R. I., Walker, K. J., Blamey, R. W.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971509/ https://www.ncbi.nlm.nih.gov/pubmed/2147110

Ejemplares similares

The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
por: Williams, M. R., et al.
Publicado: (1986)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
por: Gupta, Aanchal, et al.
Publicado: (2021)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1989)

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
por: Zhou, Juan, et al.
Publicado: (2015)

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
por: Abdel Azim, Hamdy, et al.
Publicado: (2018)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

Family history and survival in premenopausal breast cancer.
por: Mohammed, S. N., et al.
Publicado: (1998)

Body size and survival in premenopausal breast cancer.
por: Greenberg, E. R., et al.
Publicado: (1985)

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
por: Robertson, J. F., et al.
Publicado: (1992)

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial
por: Yang, H, et al.
Publicado: (2013)

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.
por: Dixon, A. R., et al.
Publicado: (1992)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro
por: Hermann, Robert M, et al.
Publicado: (2007)

Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
por: Jiang, Hang, et al.
Publicado: (2014)

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
por: Archer, S. G., et al.
Publicado: (1995)

Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?
por: Dixon, A. R., et al.
Publicado: (1993)

Update on the management of prostate cancer with goserelin acetate: patient perspectives
por: Wilson, Shandra
Publicado: (2009)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
por: Lovekin, C., et al.
Publicado: (1991)

Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer
por: Zhao, Yue, et al.
Publicado: (2021)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
por: Robertson, J. F., et al.
Publicado: (1995)

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature
por: Mahadevan, Aditya, et al.
Publicado: (2023)

P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
por: Dixon, A. R., et al.
Publicado: (1992)

Exercise activity, body size and premenopausal breast cancer survival
por: Enger, S M, et al.
Publicado: (2004)

Both Castration and Goserelin Acetate Ameliorate Myocardial Ischemia Reperfusion Injury and Apoptosis in Male Rats
por: Hadi, Najah R., et al.
Publicado: (2014)

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
por: Bouzubar, N., et al.
Publicado: (1989)

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.
por: Pinder, S. E., et al.
Publicado: (1995)

The molecular landscape of premenopausal breast cancer
por: Liao, Serena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ejbmsr0im48qs10aql5v3leeof